Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 500 of 3284 entries
View as:

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Phase: N/A Priority: Normal
NCT ID: NCT02935712 Org: User:
Start: 12/16/16 End: 01/08/18 Due: 01/08/19

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01055691 Org: User:
Start: 01/31/10 End: 04/30/10 Due: 04/30/11

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

Phase: N/A Priority: Normal
NCT ID: NCT01703260 Org: User:
Start: 06/30/13 End: 09/30/14 Due: 09/30/15

A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

Phase: N/A Priority: Normal
NCT ID: NCT00641602 Org: User:
Start: 12/31/02 End: 08/31/03 Due: 08/31/04

Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation

Phase: N/A Priority: Normal
NCT ID: NCT01562600 Org: User:
Start: 04/19/12 End: 08/27/15 Due: 08/27/16

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Phase: N/A Priority: Normal
NCT ID: NCT00912743 Org: User:
Start: 05/31/09 End: 03/31/12 Due: 03/31/13

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00423332 Org: User:
Start: 01/31/07 End: 10/31/16 Due: 10/31/17

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

Phase: N/A Priority: Normal
NCT ID: NCT01431690 Org: User:
Start: 08/31/11 End: 10/31/11 Due: 10/31/12

Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01068730 Org: User:
Start: 02/28/10 End: 04/30/10 Due: 04/30/11

Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)

Phase: N/A Priority: Normal
NCT ID: NCT01044459 Org: User:
Start: 11/30/09 End: 04/30/11 Due: 04/30/12

Study of Tremelimumab in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02527434 Org: User:
Start: 11/02/15 End: 03/28/23 Due: 03/28/24

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Phase: N/A Priority: Normal
NCT ID: NCT03036150 Org: User:
Start: 02/02/17 End: 06/12/20 Due: 06/12/21

To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days

Phase: N/A Priority: Normal
NCT ID: NCT01145768 Org: User:
Start: 06/30/10 End: 08/31/10 Due: 08/31/11

Recurrence Rate, Risk Factors for the Recurrence, and Quality of Life in Patients With GERD in Korea-an Observational

Phase: N/A Priority: Normal
NCT ID: NCT01378338 Org: User:
Start: 06/30/12 End: 09/30/13 Due: 09/30/14

Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00233623 Org: User:
Start: 07/31/04 End: 01/31/06 Due: 01/31/07

Determination of Prevalence and Features of HRRm mCRPC (ADAM)

Phase: N/A Priority: Normal
NCT ID: NCT04712890 Org: User:
Start: 10/23/20 End: 09/30/22 Due: 09/30/23

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00536107 Org: User:
Start: 10/31/07 End: 08/31/09 Due: 08/31/10

An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.

Phase: N/A Priority: Normal
NCT ID: NCT03433924 Org: User:
Start: 05/18/20 End: 03/27/23 Due: 03/27/24

Korean Post-marketing Surveillance for Onglyza®

Phase: N/A Priority: Normal
NCT ID: NCT01575483 Org: User:
Start: 03/01/12 End: 09/07/16 Due: 09/07/17

Quetiapine Fumarate Bipolar Maintenance Monotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00314184 Org: User:
Start: 03/31/05 End: 07/31/07 Due: 07/31/08

Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04991571 Org: User:
Start: 07/29/21 End: 10/22/21 Due: 10/22/22

Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler

Phase: N/A Priority: Normal
NCT ID: NCT01257048 Org: User:
Start: 08/31/11 End: 06/30/12 Due: 06/30/13

Mercury II - Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin With Rosuvastatin in High Risk Subjects With Type IIa and IIb Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT00654407 Org: User:
Start: 11/30/01 End: 09/30/04 Due: 09/30/05

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

Phase: N/A Priority: Normal
NCT ID: NCT05505162 Org: User:
Start: 08/24/22 End: 01/10/23 Due: 01/10/24

Four-period Crossover Study to Assess the Effects of Single Oral Doses of ZD4054 (Zibotentan) (10mg and 30mg) on QTc Interval

Phase: N/A Priority: Normal
NCT ID: NCT00713336 Org: User:
Start: 06/30/08 End: 11/30/08 Due: 11/30/09